Oslo, 28 April 2021: Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced
that an abstract on the Company's Phase I trial evaluating its universal cancer
vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab in
patients with metastatic malignant melanoma has been accepted for a poster
presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual
Meeting to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021.


The abstract, titled "A Phase I Clinical Trial Investigating the Telomerase
Vaccine UV1 in Combination with Pembrolizumab in Patients with Advanced
Melanoma", will provide an overview of the open-label, single-arm study
investigating the safety and tolerability for the UV1/pembrolizumab combination.


Details of the virtual poster presentation are as follows:

Title: A Phase I Clinical Trial Investigating the Telomerase Vaccine UV1 in
Combination with Pembrolizumab in Patients with Advanced Melanoma
Abstract Number: 2620
Session: Developmental Therapeutics-Immunotherapy

The corresponding abstract will be published by ASCO on Wednesday, May 19th at
5:00 pm EDT / 11:00 pm CEST. The poster presentation will be available on demand
for all conference attendees starting on Friday, June 4th at 9:00 am ET / 3:00
pm CEST. The poster will also be made available on the Company's website at the
same time on June 4th.

About UV1
UV1 is a peptide-based vaccine inducing a specific T cell response against the
universal cancer antigen telomerase. UV1 is being developed as an
"off-the-shelf" therapeutic cancer vaccine which may serve as a platform for use
in combination with other immunotherapy which requires an ongoing T cell
response for their mode of action. To date, UV1 has been tested in four phase I
clinical trials in a total of 82 patients and maintained a positive safety and
tolerability profile as well as encouraging signals of efficacy. 

About Ultimovacs
Ultimovacs seeks to become a leader in developing immune-stimulatory vaccines to
treat a broad range of cancers. Ultimovacs' lead universal cancer vaccine
candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to
be effective across the dynamic stages of the tumor's growth and its
microenvironment. By directing the immune system to hTERT antigens that are
present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor
with the goal of activating an immune system cascade to increase anti-tumor
responses. Ultimovacs' strategy is to clinically demonstrate UV1's impact in
many cancer types and in combination with other immunotherapies. The Company
will expand its pipeline using its novel TET-platform, which is an innovative
vaccine technology that can generate multiple vaccine candidates designed to
achieve increased T cell responses to a broad range of target antigens. 


For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO 
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507 

Hans Vassgård Eid, CFO 
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632